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Abstract 
Objective:  To better understand the longitudinal characteristics of Parkinson’s disease (PD) 
through the analysis of finger tapping and memory tests collected remotely using smartphones.  
Approach:  Using a large cohort (312 PD subjects and 236 controls) of participants in the 
mPower study, we extract clinically validated features from a finger tapping and memory test to 
monitor the longitudinal behaviour of study participants. We investigate any discrepancy in 
learning rates associated with motor and non-motor tasks between PD subjects and healthy 
controls. The ability of these features to predict self-assigned severity measures is assessed whilst 
simultaneously inspecting the severity scoring system for floor-ceiling effects. Finally, we study 
the relationship between motor and non-motor longitudinal behaviour to determine if separate 
aspects of the disease are dependent on one another.   
Main Results:  We find that the test performances of the most severe subjects show 
significant correlations with self-assigned severity measures. Interestingly, less severe subjects do 
not show significant correlations, which is shown to be a consequence of floor-ceiling effects within 
the mPower self-reporting severity system. We find that motor performance after practise is a 
better predictor of severity than baseline performance suggesting that starting performance at a 
new motor task is less representative of disease severity than the performance after the test has 
been learnt. We find PD subjects show significant impairments in motor ability as assessed 
through the Alternating Finger Tapping (AFT) test in both the short and long term analyses. In 
the AFT and memory tests we demonstrate that PD subjects show a larger degree of longitudinal 
performance variability in addition to requiring more instances of a test to reach a steady state 
performance than healthy subjects.  
Significance: Our findings pave the way forward for objective assessment and 
quantification of longitudinal learning rates in PD. This can be particularly useful for symptom 
monitoring and assessing medication response. This study tries to tackle some of the major 
challenges associated with self-assessed severity labels by designing and validating features 
extracted from big datasets in PD, which could help identify digital biomarkers capable of 
providing measures of disease severity outside of a clinical environment. 
Keywords: Parkinson’s disease, motor & non-motor learning, longitudinal phenotypes, digital 
biomarkers, smartphones, m-health 
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1. Introduction and Background 
The pathophysiology of Parkinson’s disease (PD) has been linked to the gradual 
degeneration of neurons within the substantia nigra, causing a lack of dopamine uptake 
in the basal ganglia (Alvarez et al. 2007). The most common symptoms of PD are often 
abbreviated as TRAP: Tremor at rest, Rigidity, Akinesia, and Postural instability 
(Jankovic 2008). In this study, we will focus on two common tests used to assess disease 
severity: the Alternating Finger Tapping test and a memory test. However, symptom 
prevalence, progression, and severity are highly inhomogeneous across the PD population 
making diagnosis and quantification of medication efficacy challenging. (Michell et al. 
2004; Robbins & Cools 2014).  
 
The most popular means of assessing the severity of PD is the Movement Disorder 
Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (Goetz et al. 2008). The 
MDS-UPDRS is clinic based scoring system in which 65 motor and non-motor evaluations 
are made: each on a scale of zero (normal) to four (severe). Though widely used, the MDS-
UPDRS is commonly corrupted by inter- and intra-rater variability as well as subjectivity 
(Antoniades et al. 2013; Das et al. 2011; Goetz et al. 2002). In a recent study, the mean 
difference in inter-rater UPDRS variability was reported to be between 1.7 and 5.4, 
whereby nurses, residents and movement disorder specialists (MDS) were found to 
consistently assign higher UPDRS scores as compared to senior MDS (Post et al. 2005). 
Although the ‘Floor-Ceiling’ effect is often small in the full clinically administered UPDRS 
system, the effect remains unknown in many abridged systems whilst being remotely self-
reported in large cohorts (Goetz et al. 2008; Gallagher et al. 2012). The floor-ceiling effect 
occurs in a scoring system when the extremity scores are insensitive to small changes in 
the parameter being measured, resulting in a high proportion of scores taking the highest 
or lowest possible values.  
 
The current requirement for PD diagnosis and treatment to be performed in-clinic not 
only incurs a substantial cost for healthcare services but also can be challenging for 
elderly sufferers of PD living in rural areas as most neurologist tend to be based in urban 
areas. Additionally, with the projected number of people with PD to increase dramatically 
over the next decade, the ability to reliably perform assessments outside of a clinical 
environment is highly desirable (Dorsey et al. 2007). These challenges, in addition to the 
shortcomings of the MDS-UPDRS, have led to an active area of research identifying 
objective biomarkers to quantify the severity symptoms associated with PD though the 
use of digital sensors (Kubota et al. 2016; Rovini et al. 2017). A range of sensors have 
shown capabilities of objectively assessing symptoms including microphones for voice 
analysis and accelerometers for movement analysis such as gait, tremor, and dexterity 
(Tsanas et al. 2010; Bayestehtashk et al. 2015; Patel et al. 2009; Horak & Mancini 2013; 
LeMoyne et al. 2013; Kassavetis et al. 2016). The benefit of using sensors is that they 
enable objective digital biomarkers to be identified which could be used as complimentary 
measures of disease severity along with clinical scores.  
 
In a clinical environment, the Alternating Finger Tapping (AFT) activity has 
demonstrated that subjects with PD show an impaired motor-performance when 
compared to healthy subjects (Memedi et al. 2013; Okuno et al. 2006; Jobbágy et al. 2005). 
Such impairments include hastening, faltering, or freezing during the AFT test. 
Subsequently, these impairments have been detected through digital sensors resulting in 
features such as tapping speed and rhythm being identified as showing strong capabilities 
of predicting symptom severity (Tavares et al. 2005; Printy et al. 2014). Additionally, 
quantitative approaches to detecting non-motor impairment in PD subjects have also 
shown promise through memory examinations such as the Serial Reaction Time (SRT) 
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Test. Findings commonly suggest that subjects with PD show impaired sequence and 
implicit learning when compared to healthy subjects (Helmuth et al. 2000; Muslimović et 
al. 2007; Siegert et al. 2008).  
 
However, the primary downfall of previous studies utilising wearable sensors lie in the 
fact that they suffer from low subject numbers and lack of longitudinal data as they were 
confined to a hospital environment, which seriously limits the scalability of these studies 
as data collected in a home environment can be more confounded by noise. Table 1 
provides a summary of the most recent AFT studies demonstrating their subject and 
instance limitations. Presently, the degree of scalability of previous findings is unknown 
as validation on long time-scales, on a large subject group, and in a non-clinical lab 
environment has yet to be undertaken. Furthermore, both the motor and non-motor 
learning impairments discovered in subjects with PD have only been suggested over a 
very short period of time (usually within 24 hours), commonly over the course of several 
test repetitions  or a single clinical visit (Tanaka et al. 2000; Jobbágy et al. 2005). 
 
 
Author 
# 
Subjects 
(PD/HC) 
# Of 
Measurements 
Measurement Device Location 
(Arroyo-gallego et al. 2017) 21 / 23 51 Smartphone Clinic 
(Kassavetis et al. 2016) 14 / 0 14 1 Smartphone Clinic 
(Picillo et al. 2016) 123 / 0 492 2 Video camera Clinic 
(Arora et al. 2015) 10 / 10 18 3 Smartphone Remote 
(Printy et al. 2014) 18 / 0 54 Smartphone & Glove Clinic 
(Memedi et al. 2013) 95 / 10 12,011 4 Personal Handheld Computer Clinic & Remote 
(de Frias et al. 2007) 50 / 48 196 Custom Response Console Clinic 
(Tavares et al. 2005) 33 / 0 66 MIDI-Keyboard Clinic 
(Lee et al. 2016) 57 / 87 432 
Smartphone & Mechanical 
Tapper 
Clinic 
(Zhan et al. 2016) 121 / 105 1,600 5 Smartphone Remote 
mPower (Bot et al. 2016) 8,003 78,887 
Smartphone Remote 
mPower (used in this study) 312 / 236 48,892 
Table 1: Summary of the most recent studies quantifying a tapping activity in Parkinson's disease. The data 
collected in the mPower study, shown in the bottom row, is used in this study. Of the 8,003 subjects, the 
PD/HC split is 1,060/5,357, with 1,586 participants not providing a diagnosis label. 
1 Not stated, assumed to be one measurement per subject. 
2 One measurement for each hand in each medication state (ON/OFF) 
3 Average of 2.7 tests per day for an average of 34.4 days (~93 tests) assumed to be split evenly over 5 tests types. 
4 Coming from multiple studies. Measurement frequency is highly inconsistent with ~28 to 2 measurements per subject 
and no longitudinal analysis was performed. 
5 8,000 instances in the study are assumed to be split evenly across five modalities (voice, gait, balance, reaction, dexterity)  
 
The advancement of micro-electronic systems has enabled wearable sensors to become 
more commonplace in everyday life, most notably though their embedment in 
smartphones. Recent studies into PD have created smartphone applications enabling 
participants to perform tests multiple times a day, over the course of many months, all in 
a non-clinical environment (Zhan et al. 2016; Bot et al. 2016). The accelerometer in 
smartphones allows assessment of gait, tremor, and balance, whilst the touch-screen is 
used for the AFT activity and for memory games. Subsequently, these studies have 
collected databases which contain tests over multiple modalities on a longitudinal basis 
from greatly increased subject numbers. Smartphones also enable the user to perform 
regular self-assessments regarding their disease severity, symptom prevalence, and 
medication adherence. However, many challenges have been identified when collecting 
remote data compared to clinical data (Kubota et al. 2016; Neto et al. 2017). The 
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variability of test environment and smartphone placement and orientation have a 
significant influence on the test data. It is challenging to determine whether differences 
between tests are due to environmental factors or caused by a longitudinal change in 
impairment.  
Findings from clinical datasets suggest subjects with PD show impairments in motor and 
non-motor learning in the AFT and memory tests on a short term basis (Siegert et al. 
2008; Tanaka et al. 2000). There are three main contributions of this study: (1) we 
investigate for the first time whether longitudinal motor and non-motor learning 
impairments can be detected in the large and remotely collected mPower dataset (2) we 
explore how changes in longitudinal test performance can be quantified and used to better 
predict disease severity measures and (3) by inspecting the individual elements of the 
disease severity scores we reveal limitations in the self-assessed UPDRS system. 
2. Methods 
2.1 Data 
The data used here was collected during the first six months of the mPower Study (Bot et 
al. 2016). Volunteer participants enrolled in the study through the mPower iPhone (Apple 
Inc., Cuppertino, USA) application. 
Using the application, participants self-report their severity and symptoms through a 
subset of UPDRS Section I (non-motor experiences of daily living) and Section II (motor 
experiences of daily living) questions. Unlike the other sections of the full UPDRS, 
Sections I and II have been specifically designed to be completed without the help from a 
movement disorder specialist (Goetz et al. 2008). A demographic survey was completed on 
a one off basis by 6,805 participants allowing them to describe their health history 
including whether they have been professionally diagnosed with PD. Participants were 
asked to complete the UPDRS survey at baseline and then on a monthly basis throughout 
the study. The UPDRS survey was completed a total of 2,305 times by 2,024 unique 
participants.  
The smartphone application presents the participants with four measurement activities: 
Walking, Voice, Tapping, and Memory. This research focuses on the tapping and memory 
activities as these will be new to the participants, have been widely studied in-clinic, and 
shown to demonstrate learning behaviour. For the tapping activity, participants were 
asked to perform the AFT task for 20 seconds. This entails placing the smartphone on a 
flat surface and alternately tapping the screen using the index and middle finger as fast 
as possible. The data provided by this activity are the timestamps (time of finger touching 
the screen) and the {x,y} screen pixel coordinates for each tap instance. Although many 
features from the AFT have shown to be discriminative between PD and HC subjects, we 
focus on the total number of taps (equivalent to average tapping speed) as this measure 
is easily interpretable and has repeatedly been validated clinically, often showing the 
strongest relation to severity (Tavares et al. 2005). The tapping activity was completed 
78,887 times by 8,003 unique participants. 
The memory activity was included in the mPower study in a later version than the other 
activities and subsequently has significantly fewer test instances. The activity consists of 
showing the participant a sequence of lighting up flowers arranged in a grid, and then 
asking the participant to replicate the sequence in order. This process is repeated three 
times with the grid becoming larger and the sequence more challenging with each 
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iteration. The resulting raw data provided by this activity are the total score, the number 
of failures, as well as the tap coordinates and time intervals for completing each level – of 
which we focus on the total score. The memory activity was completed 8,569 times by 968 
unique participants. 
2.2 Analysis Procedures 
2.2.1 Short Term Behaviour 
It has been shown in clinical environments that PD and HC participants show variable 
performances over a small number of repetitions at the AFT test (Tanaka et al. 2000). 
Firstly, we aim to determine if PD participants show an impaired performance at the AFT. 
Secondly, we investigate whether the PD participants’ performance changes at a different 
rate to HCs over a short number of repetitions and whether these changes could be 
induced by a response to medication; enabling the differentiation of the performance 
change due to learning from the performance change due to medication.  
In the tapping activity, to be included in the short term behaviour (STB) analysis, 
participants were required to have contributed 5 or more test instances within the first 
24 hours of their first test instance (n = 600). Due to the lower number of participants and 
instances in the memory activity, the inclusion criteria was altered so that participants 
who contributed 5 or more test within the first 72 hours of their first test were included 
(n = 112).  
By inspecting the relative test performances between the PD and HC participant groups 
we can determine whether PD participants show impairment at baseline. Next, we 
compare the performance of each participant group after the fifth repetition of an activity 
with their baseline performance using the student t-test. Our choice of limiting this 
analysis to the first five tests is based on previous works demonstrating that both the AFT 
and SRT tests show learning within five repetitions (Muslimović et al. 2007; Behrman et 
al. 2000). In order to determine if medication is having an effect on test performance, we 
repeat the above procedure on all participants who are in the same medication state at 
baseline and at fifth visit, thus isolating the change in performance due to practise via 
removing any influence of medication.   
2.2.2 Longitudinal Behaviour 
Previous studies focus on the short term behaviour of the AFT test as they did not have 
access to longitudinal tests (Table 1). As we have access to longitudinal data, we extend 
the analysis to determine whether longitudinal variation occurs within the performance 
of HC and PD participants. Adopting a similar approach to the study of the short term 
behaviour, we investigate whether PD participants are more likely to show transient 
behaviour and whether the rate at which PD participants learn new tasks is different to 
HCs. As each test is labelled with a medication timestamp, we determine if PD 
participants who are not taking medication are more likely to show transient behaviour 
than those who are taking medication. This high-frequency analysis may provide useful 
insight into the effect of medication on test performance, and help clinicians make 
informed decisions to optimize drug dosage and times for each individual PD participant. 
For the tapping test, any participant who contributed 20 or more tapping test instances 
is included in the long term behaviour (LTB) analysis (548 participants). Alternatively, 
due to there being less memory test instances, any participant who contributed 10 or more 
memory test instances is included in the long term behaviour analysis (121 participants). 
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Progress Ratio 
To quantify the longitudinal performance of a participant we define the Progression Ratio 
(PR) metric. The PR continuously compares a participant’s average starting performance 
to their performance at any other given test instance. When this process is repeated for 
all instances we get multiple PR values which form the Progression Ratio Waveform 
(PRW). 
If a participant completes a total of N instances of a test, and we select an averaging 
window size of n (where N>>n) we are able to calculate a PRW with J = N – (n-1) test 
points. The jth point in the PRW is calculated via: 
𝑃𝑅𝑊𝑗 =
1
𝑛 
∑ 𝑓𝑗
𝑗+(𝑛−1)
𝑗
𝜇𝐵𝑉
 
Equation 1 
where: 
𝜇𝐵𝑉 =  
1
𝑛
 ∑ 𝑓𝑗
𝑛
𝑗=1
 
Equation 2 
with fj being the feature value at test number j. The PRW is taking the average feature 
performance over the first n tests, and then finding the ratio between this average 
starting performance and the average performance of all other windows (of length n). In 
this study, we set n = 5. The averaging window size of five is used as this is consistent 
with and builds on our previous short term analysis which focused on the first five test 
performances. This enables us to separate the learning behaviours seen in the short and 
long term analyses.  
According to Equation 1, if a feature value increases over repetition, the PRW will tend 
to be greater than one, whereas if the feature value decreases over repetition, the PRW 
will be less than one. A feature showing little or no change over time will have a PRW at 
a constant value of one. We classify participants into Learning-Phenotypes (L-PTs) based 
on 𝜇prw, the mean of their PRW, according to: 
𝐿 − 𝑃𝑇 =  {
𝜇𝑝𝑟𝑤  > 1.2
𝜇𝑝𝑟𝑤  < 0.8
0.8 ≤  𝜇𝑝𝑟𝑤  ≤ 1.2
  
𝐼𝑚𝑝𝑟𝑜𝑣𝑖𝑛𝑔
𝐷𝑒𝑡𝑒𝑟𝑖𝑜𝑟𝑎𝑡𝑖𝑛𝑔
𝑆𝑡𝑎𝑏𝑙𝑒
 
Equation 3 
The 𝜇prw therefore enables us to determine if a participant’s performance is varying 
longitudinally. In Equation 3, the thresholds for classification are based on observing an 
average performance change of 20% from baseline. Previous investigations into short term 
learning in the AFT and reaction time tests report performance changes of between 16 - 
24% (Light et al. 1996; Tanaka et al. 2000). As the data in this study is collected remotely, 
test performances can vary as a consequence of test environment, thus, using a value of 
20% ensures only subjects who show a consistently different longitudinal performance 
with their baseline performance are classified as being either improving or deteriorating. 
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Steady State Index 
In addition to detecting the presence of transient and varying longitudinal performance 
in a new task, we want to determine if PD participants take longer to learn this task. We 
now define the Steady State Index (SSI), a metric which estimates the test number at 
which a participant reaches a steady state of performance. The SSI continuously compares 
a participant's average performance over their final n tests, which is assumed to be their 
Steady State Performance (SSP), to their performance at any other test instance. In the 
same manner as we calculated the progression ratio waveform, we now calculate the 
Steady State Waveform (SSW) as: 
𝑆𝑆𝑊𝑗 =
1
𝑛 
∑ 𝑓𝑗
𝑗+(𝑛−1)
𝑗
𝑆𝑆𝑃
 
Equation 4 
where: 
𝑆𝑆𝑃 =  
1
𝑛
 ∑ 𝑓𝑗
𝑁
𝑗 = 𝑁−𝑛
 
Equation 5 
Whereas for the progression ratio waveform we find the ratio between current 
performance and the mean starting performance, when determining the SSW we find the 
ratio between the current performance and the mean finishing performance. In order to 
determine the Steady State Index, we find the indices of tests whose performances are 
within 20% of the SSP: 
𝑰 = (𝑆𝑆𝑊 < 1.2) & (𝑆𝑆𝑊 > 0.8) 
Equation 6 
From the binary I vector, the index of the first two consecutive TRUE instances is set as 
the SSI.  
2.2.3 Relation to Disease Severity 
Features from the AFT activity and memory function tests have been shown to correlate 
well with clinically assigned severity. (Tavares et al. 2005; Sahakian et al. 1988; Aarsland 
et al. 2010). However, the above studies have mostly consisted of one-off clinical visits on 
a small cohort of subjects with mild/severe severities. The above findings are yet to be 
tested on a large cohort of subjects, using remotely collected data, encompassing a wide 
range of UPDRS severity scores.  
We expand on previous approaches via incorporating the longitudinal progression of 
participant performance. To investigate the potential links between longitudinal 
performances and disease severity we find the correlation between disease severity and 
participants’ steady state performances and compare this with the correlation between 
disease severity and baseline performances.  
The PD participants who were included in the Longitudinal Behaviour Subset and who 
also had at completed least one UPDRS assessment were included in this analysis. This 
subset is herein referred to as the Performance-Severity Subset (PSS).  
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We further explore the reliability of the mPower UPDRS survey via determining if the 
‘Floor-Ceiling’ effect is present in the mPower subset of questions. Firstly, we divide PSS 
into two groups based on their total UPDRS score severity. We compare the correlation 
between the test performances and severity scores of severe participants against the same 
correlation in not-severe participants. A participant is labelled as Severe if their total 
UPDRS score is above the mean plus one standard deviation of the population’s total 
UPDRS score (UPDRS threshold = 20.0). Secondly, we divide participants into two groups 
based on the test performances. We compare the correlation between the test 
performances and severity scores of participants with severely impaired performances 
against the same correlation in participants whose performances are not severely 
impaired. A participant is labelled as having a severe performance if their baseline 
performance is below the mean minus one standard deviation of the population’s baseline 
performance (tapping threshold = 99.1 and memory threshold = 191.8). Finally, we 
investigate the relationship between disease severity and the number of years since 
diagnosis. This is firstly performed on all PD participants who contributed a UPDRS 
survey (N = 534). Secondly, we split the PSS cohort into two groups based on how recently 
the participants received their professional diagnosis. We find the correlation between the 
years since diagnosis and the participants’ UPDRS scores and test performances. A 
participant is labelled as having a recent diagnosis if they received their diagnosis within 
the last seven years. Conversely, a participant is labelled as having a longstanding 
diagnosis if they have had a diagnosis for seven years or longer. The seven year threshold 
was chosen as it is the mean plus one standard deviation1 of the years of diagnosis for PD 
participants in both the tapping and memory tests. Finding these correlations, in a large 
population with a wide range of severity scores, will enable us to comment on whether 
previously clinically found features are suitable for severity prediction on subjects with 
low/mild severities in a remote environment. Finally, for each individual question in the 
mPower UPDRS survey, as well as the total UPDRS score, the floor-ceiling effects are 
evaluated via calculating the percentage of responses that are the highest and lowest 
possible values.  
2.2.4 Relationship between Tapping and Memory Tasks 
The final analysis aims to find if a relationship exists between the longitudinal behaviour 
in the tapping and memory activities. We identify all participants who were in the 
Longitudinal Behaviour Subsets for both the tapping and memory activities (n = 107) and 
determine if their longitudinal behaviour is consistent between the activities. 
2.2.5 Disease Characteristics between Sexes 
It has been suggested that oestrogens may have a neuroprotective effect against PD; in 
animals the substantia nigra has shown to be more susceptible to neuron degradation in 
low oestrogen environments (Datla et al. 2003). Several studies have demonstrated that 
PD incidence can be as much as two times higher in males than in females (Haaxma et 
al. 2007). Subsequently, due to their lower oestrogen levels, it is proposed that males are 
more likely to develop PD at a younger age than females.  
Utilizing the entire mPower demographics dataset, we investigate if the proportion of 
male and female participants with PD is in agreement with previously reported incidence 
between sexes. For the PD participants who completed the demographics survey and at 
                                               
1 From the mPower demographics survey it is only possible to calculate the year since diagnosis to the closest 
integer we therefore round our threshold down to the nearest integer. 
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least one tapping test (N = 1,060) or at least one memory test (N = 297) we study the 
effects of sex on smartphone test performance (as quantified using the number of taps and 
memory score). We conclude our study on disease characteristics between sexes via 
implementing Binomial proportion tests between the male and female participants within 
each of the L-PTs. This is performed for the tapping and memory tests, and is aimed to 
determine whether participant sex is a confounding factor in L-PT classification. 
2.2.6 Data Subsets 
For the first two analysis sections outlined above, we further divide the eligible 
participants into three subsets; Young Healthy Control, Age Matched Healthy Controls, 
and Parkinson’s Disease participants. These three groups are denoted by YHC, HC, and 
PD respectively. The YHC subset contains any participant under the age of 50 years old 
who self-reports as not having PD. The HC subset contains any participants who are 50 
years old or older and who report as not having PD. The PD group contains any 
participant who self-reports as having a professional diagnosis of PD. 
  Tapping Memory 
  # Age UPDRS # Age UPDRS 
Short Term 
Behaviour 
YHC 406 30.2 ± 8.8 N/A 10 32.8 ± 12.1 N/A 
HC 57 60.3 ± 7.7 N/A 11 64.2 ± 10.4 N/A 
PD 137 63.4 ± 7.3 N/A 91 65.5 ± 6.2 N/A 
Longitudinal 
Behaviour 
YHC 150 32.5 ± 9.5 N/A 10 34.3 ± 9.1 N/A 
HC 86 61.9 ±7.7 N/A 14 65.1 ±7.0 N/A 
PD 312 63.8 ± 6.8 N/A 97 65.6 ± 6.3 N/A 
Performance 
Severity 
Subset 
Severe UPDRS 28 64.3 ± 6.2 27.6 ± 4.1 16 65.5 ± 7.3 25.8 ± 3.2 
Not Severe UPDRS 233 63.9 ± 6.8 9.6 ± 5.9 67 63.8 ± 6.5 9.6 ± 5.6 
Severe Perf 59 63.6 ± 6.8 13.5 ± 8.1 9 64.1 ± 6.4 13.4 ± 7.7 
Not Severe Perf.  204 63.9 ± 6.7 10.5 ± 7.4 74 63.6 ± 6.5 10.5 ± 6.9 
Longstanding Diagnosis 48 62.6 ± 7.5 17.0 ± 8.8 18 64.9 ± 7.5 16.5 ± 7.32 
Recent Diagnosis 215 64.1 ± 6.5 11.5 ± 6.8 65 65.8 ± 6.0 11.3 ± 6.3 
Table 2: The characteristics of participants in each of the three main analysis subsets. The Short-Term 
Behaviour (STB) and Longitudinal Behaviour (LTB) subset inclusion criteria do not require participants to 
have contributed a UPDRS survey, they therefore contain many participants who did not contribute any 
UPDRS data and hence this has been omitted.  
3. Results 
3.1 Tapping 
3.1.1 Short-Term Behaviour 
At baseline performance, PD participants show significant impairment compared to both 
HC [p <0.001] and YHC [p <0.001] participants. Similarly, after five repetitions PD 
participants remain significantly impaired compared to HC [p = 0.02] and YHC [p < 0.001] 
participants. 
Performing paired t-tests between the baseline performance and performance at the fifth 
repetition for the YHC, HC, and PD groups yields p-values of 0.60, 0.27, and 0.03 
respectively, demonstrating that the only participant group showing a significant level of 
change at the 0.05 level are the PD participants.  
Further, for all participants we find that the change in performance over the first five test 
instances correlates with baseline performance [R = -0.48]. This intuitively states that 
participants with a lower baseline performance tend to improve by a larger degree than 
participants at a higher baseline performance.  
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Across each of the first five test instances, the PD participants showed a higher level of 
performance variability (58 ± 1.25 taps) than both the HC (48 ± 1.8 taps) and YHC (47.8 
± 1.3 taps) subsets.  
Of the 137 PD participants, 11 reported that do not take any medication for their 
Parkinson’s disease symptoms, and the remaining 126 participants reported taking 
medication. No difference is seen in baseline performance between participants who take 
medication and those who do not [p=0.58].  
Of the 126 participants who take medication, 22 reported being in the OFF state (‘before 
medication’) and 33 reported being in the ON state (‘after medication’) at baseline. No 
difference is seen in performance between the participants in the ON and OFF states [p 
= 0.59]. Seventy participants were identified as being in the same medication state at 
baseline and at fifth visit. These participants also showed a significant change between 
baseline and fifth visit [p = 0.04] thus demonstrating that the significant changes in 
performance are not a response to medication. 
3.1.2 Longitudinal Behaviour 
In the Longitudinal Behaviour Subset data, we find significant impairment between the 
PD and HC participants [p<0.001] and the PD and YHC participants [p<0.001] in baseline 
performance. 
Each participant’s Learning-Phenotype is determined based on Equations 1 and 3. The 
longitudinal performance of each participant group, and each of the three L-PTs, can be 
seen in Figure 1. 
 
Figure 1: The longitudinal behaviour over the first 20 test instances in the tapping activity for participants 
identified as (a) improving (b) deteriorating and (c) stable. 
 
 % of Sub-
Group 
Baseline Value 
(±SD) 
Final Value 
(±SD) 
Progress 
Ratio (±SD) 
Steady State 
Index (±SD) 
YHC 
(n = 150) 
Imp. 5.3 96.0 ± 51.6 182.8 ± 94.9 1.33 ± 0.18 5.3 ± 4.1 
Det. 2.0 172.3 ± 9.5 122.7 ± 68.1 0.78 ± 0.02 7.3 ± 1.5 
Stab. 92.7 183.9 ± 43.5 180.0 ± 43.4 1.00 ± 0.07 2.0 ± 4.5 
HC 
(n = 86) 
Imp. 12.8 80.64 ± 16.8 115.82 ± 51.5 1.30 ± 0.09 4.3 ± 3.1 
Det. 0 N/A N/A N/A N/A 
Stab. 87.2 157.03 ± 43.4 164.99 ± 35.5 1.01 ± 0.08 1.1 ± 1.0 
PD 
(n = 312) 
Imp. 15.7 81.65 ± 45.5 136.39 ± 57.4 1.46 ± 0.45 16.6 ± 26.6 
Det. 4.5 146.57 ± 70.2 76.57 ± 30.1 0.71 ± 0.08 11.3 ± 10.7 
Stab. 79.8 136.81 ± 54.7 139.95 ± 54.9 1.01 ± 0.09 2.3 ± 5.4 
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Table 3: Baseline and longitudinal characteristics of each of the three Learning Phenotypes in the three 
participant groups in the tapping activity. 
Over 20 test instances, the improving YHC, HC, and PD participants increased their 
performance by an average of 75, 86, and 40 taps respectively [Figure 1(a)]. The improving 
PD and HC participants showed a significant difference between their baseline 
performance and 20th test performance, both with p<0.001, whereas the improving YHC 
participants approached significance with p=0.051. 
 
No significant changes in performance were seen for any of the stable YHC, HC, or PD 
participants. The stable PD participants maintained a significant impairment in 
performance compared to the HC and YHC participants over the first 20 test instances 
[Figure 1(c)]. 
 
The proportion of each sub-group showing transient (not stable) behaviour can be seen in 
Table 3. The Binomial proportional test is used to determine if PD participants are more 
likely to show transient behaviour than HCs. We find a significantly larger proportion of 
PD participants show transient behaviour compared to the YHC participants [Z = 3.67, p 
< 0.001] whereas the proportion of PD and HC participants showing transient behaviour 
approaches significance [Z = 1.56, p = 0.059]. To account for the effects of age, a Binomial 
proportional test was also performed between the YHC and HC participants yielding 
insignificant differences in the number of transient participants between the groups [p = 
0.134]. 
 
In addition to determining if PD participants are more likely to show transient behaviour, 
we use the Steady State Index (SSI) to measure if PD participants take longer to learn a 
task. The PD participants show significantly larger SSI values than the HCs [p = 0.013] 
and YHCs [p = 0.015]. Further dividing the PD group into its L-PTs  (final column of Table 
3), we see that this difference is caused by the much larger SSIs of the improving and 
deteriorating participants. Across the entire Longitudinal Behaviour subset, the time (in 
days) of each test relative to the first test is found to correlate very highly with test index 
[Pearson R = 0.95], validating that SSI is a suitable measure for time taken to reach a 
steady state. 
 
Of the 312 PD participants in the Longitudinal Behaviour Subset, 24 self-reported as not-
medicated, and the remaining 288 as medicated. Six of the non-medicated participants 
showed transient behaviour and the remaining 18 were stable. We found no difference 
between the proportion of medicated participants that showed transient behaviour 
compared to non-medicated participants [Z = 0.28, p = 0.77]. 
 
3.1.3 Severity Correlation 
Prior to splitting the Performance-Severity Subset (PSS) based on severities, from the 
first row of Table 4 we see that in all cases the steady state performance has a stronger 
correlation with severity than baseline performance. 
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Figure 2: The relationship between years since diagnosis and total UPDRS for all PD participants in the 
mPower dataset who contributed a UPDRS survey.  
  Total UPDRS Section II UPDRS UPDRS 2.4 
 L-PT Baseline 
Steady 
State 
Perf. 
Baseline 
Steady 
State 
Perf. 
Baseline 
Steady 
State 
Perf. 
 All Severities -0.15 -0.22 -0.16 -0.21 -0.17 -0.24 
Total 
UPDRS 
Severe -0.36 -0.54 -0.32 -0.41 -0.27 -0.47 
Not Severe -0.17 -0.19 -0.18 -0.19 -0.16 -0.20 
Tapping 
Severe -0.37 -0.49 -0.36 -0.40 -0.34 -0.43 
Not Severe -0.04 -0.11 -0.06 -0.09 -0.09 -0.17 
Table 4: Spearman correlation coefficients between Baseline Values (BV) and Steady State Performances 
(SSP) with severity scores for the tapping activity with significant correlations (at the 0.05 level) shown in 
bold.  
When splitting the PSS based on UPDRS severity, we again observe that in all cases the 
steady state performance has a stronger correlation with severity when compared to the 
baseline performance. Similarly, when splitting the PSS based on tapping performance, 
we find the steady state performance to have a stronger correlation with severity than 
baseline performance.  
In both splitting approaches, we find that the performance of severe participants 
systematically have stronger correlations with severity scores when compared to non-
severe participants. Further, we find that splitting the participants in such a way 
produces statistically significant correlations of increased and moderate strengths.  
In addition to correlating tapping performance with the total UPDRS and Section II 
UPDRS (motor experiences of daily life) scores, we found that UPDRS 2.4 (‘Over the past 
week have you usually had troubles handling your food and easting utensils’) also 
correlated significantly with performance in both splitting techniques. 
  UPDRS Performance 
  Total Section II UPDRS 2.4 Baseline 
Steady 
State Perf. 
 All Diagnoses 0.34 0.36 0.23 0.02 0.05 
Diagnosis  
Longstanding 0.35 0.41 0.38 0.02 0.06 
Recent 0.25 0.23 0.11 0.02 0.04 
Table 5: Spearman correlation coefficients between participants’ years since diagnosis and their severity 
scores and tapping performances with significant correlations (at the 0.05 level) shown in bold. 
Further, we found weak correlations between years since diagnosis and age in the 
Longstanding Diagnosis group (R = 0.01) and in the recent diagnosis group (R = 0.03). 
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The UPDRS floor effects were large within each of the 16 individual questions. On 
average, 47.1% of responses to each question were the lowest possible score (0 – ‘Normal’). 
Conversely, the ceiling effects within each question were small, with an average ‘Severe’ 
response rate of 1.0% with six of the questions not containing any ‘Severe’ subjects. The 
UPDRS 2.4 question consisted of 54.2% ‘Normal’ responses whereas no instances of the 
maximum score of four (‘Severe’) were reported. These effects are not reflected in the total 
UPDRS score (summation of each question) with no subjects reporting the lowest or 
highest scores possible (zero and 64 respectively). 
3.2 Memory 
 
3.2.1 Short-Term Behaviour 
At baseline performance, the 91 PD participants showed no significant memory 
impairment (as quantified using the total memory score) compared to the 11 HC and the 
10 YHC participants. However, after five repetitions PD participants differed from the 
YHC group significantly [p = 0.04].  
Performing paired t-tests between the baseline performance and performance at the fifth 
repetition for the YHC, HC, and PD groups yields p-values of 0.29, 0.15, and 0.04 
respectively. This finding is consistent with the equivalent result in the tapping activity 
and demonstrates that the only participant group showing a significant level of change at 
the 0.05 level are the PD participants.  
For all participants we again find that the change in performance over the first five test 
instances correlates with baseline performance [R = -0.49], showing that participants with 
a lower baseline memory performance are more likely to improve than participants with 
a higher baseline performance. 
3.2.2 Longitudinal Behaviour 
In the Longitudinal Behaviour Subset data, we find there to be no significant memory 
impairment between PD, HC, or YHC participants in baseline performance. The small 
sample size available is noted when drawing conclusions from these tests.  
 
Figure 3 : The longitudinal behaviour over the first 10 test instances in the memory activity for participants 
identified as (a) improving (b) deteriorating and (c) stable. Note: a higher memory score denotes better test 
performance.  
Over 10 test instances, the improving YHC, HC, and PD participants increased their 
memory score by an average of 47.5, 80.0, and 80.4 points respectively [Figure 3(a)] 
although none of the improving groups showed a significant change between baseline and 
10th instance performance. 
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The proportion of each sub-group showing transient behaviour can be seen in Table 5. 
Due to the insufficient number of participants in each of the YHC and HC Binomial 
proportion tests are inappropriate. 
 
 
 
% of Sub-
Group 
Baseline 
Value (±SD) 
Final 
Value (±SD) 
Progress 
Ratio 
(±SD) 
Steady 
State Index 
(±SD) 
YHC 
(n = 10) 
Imp. 20.0 195.0 ± 63.6 225.00 ± 63.6 1.26 ± 0.12 5.5 ± 3.5 
Det. 40.0 287.5 ± 42.1 223.75 ± 19.7 0.86 ± 0.03 5.3 ± 2.5 
Stab. 40.0 233.8 ± 17.5 235.00 ± 55.8 1.01 ± 0.06 1.0 ± 0 
HC 
(n = 14) 
Imp. 14.3 202.5 ± 10.6 300.0 ± 56.6 1.16 ± 0.03 1.5 ± 0.7 
Det. 7.1 295.0 ± 0 240.0 ± 0 0.87 ± 0 7 ± 0 
Stab. 78.6 273.6 ± 47.2 254.6 ± 62.1 0.98 ± 0.04 1.0 ± 0 
PD 
(n = 97) 
Imp. 21.7 200.9 ± 47.1 255.0 ± 65.5 1.24 ± 0.19 5.8 ± 6.2 
Det. 7.2 323.6 ± 36.6 231.4 ± 44.2 0.80 ± 0.10 11.6 ± 13.5 
Stab. 71.1 257.3 ± 51.4 255.9 ± 52.7 0.99 ± 0.05 1.8 ± 4.8 
Table 6: Baseline and longitudinal characteristics in the memory activity of each of the three Learning 
Phenotypes in the three participant groups. 
No difference is found between any of the group SSI values. We see in Table 5 that the 
deteriorating PD participants have the longest average SSI, although this L-PT is also 
restricted in participant numbers (n = 7). 
 
 
3.2.3 Severity Correlation 
From the first row of Table 6 we find that the steady state performance tends to have a 
weaker correlation with severity than baseline performance. This result is also seen when 
splitting the participants based on UPDRS severity and based on performance 
impairment. 
  Total UPDRS Section I UPDRS UPDRS 1.1 
 L-PT Baseline 
Steady 
State 
Perf. 
Baseline 
Steady 
State 
Perf. 
Baseline 
Steady 
State 
Perf. 
 All Severities -0.14 -0.04 -0.16 0.08 -0.01 -0.03 
Total 
UPDRS  
Severe -0.43 -0.10 -0.18 -0.08 -0.33 -0.20 
Not Severe -0.13 -0.01 -0.17 -0.14 -0.01 0.06 
Memory 
Severe -0.33 -0.08 -0.51 -0.16 -0.36 -0.01 
Not Severe -0.03 -0.01 -0.06 -0.19 -0.13 -0.09 
Table 7: Spearman correlation coefficients between Baseline Values (BV) and Steady State Performances 
(SSP) with severity scores for the memory activity with significant correlations shown in bold. 
However, in both splitting approaches the performance of the severe/impaired 
participants have stronger correlations with severity scores than when compared to non-
severe/non-impaired participants. Consistent with the equivalent results in the tapping 
analysis, we again find that the severe/impaired participants produce several statistically 
significant correlations with moderate strength.   
In addition to correlating memory performance with the total UPDRS and Section I 
UPDRS (non-motor experiences of daily life) scores, we found that UPDRS 1.1 (‘Over the 
past week have you had problems remembering things, following conversations, paying 
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attention, thinking clearly, or finding your way around the house or in town?’) also 
correlated significantly with performance in both splitting techniques. 
  UPDRS Performance 
  Total Section I UPDRS 1.1 Baseline 
Steady 
State Perf. 
 All Diagnoses 0.35 0.19 0.04 -0.11 -0.10 
Diagnosis 
Longstanding 0.10 0.06 0.04 -0.19 0.02 
Recent 0.22 0.19 0.02 -0.17 -0.05 
Table 8: Spearman correlation coefficients between participants’ years since diagnosis and their severity 
scores and tapping performances with significant correlations (at the 0.05 level) shown in bold. 
Again, we found weak correlations between years since diagnosis and age in the 
Longstanding Diagnosis group (R = 0.07) and in the recent diagnosis group (R = 0.04). 
The UPDRS floor effects were again large within each of the 16 individual questions. On 
average, 47.8% of responses to each question were the lowest possible score. Consistent 
with the tapping activity, the ceiling effects within each question were small, with an 
average ‘Severe’ response rate of 0.7%. In 13 of the questions, no subjects reported a 
‘Severe’ score. The UPDRS 1.1 question consisted of 54.8% ‘Normal’ responses whereas no 
subjects reported the maximum score of four (‘Severe’). These effects are not seen in the 
total UPDRS score (summation of each question) with no subjects reporting the lowest or 
highest scores possible.  
3.3 Disease Characteristics between Sexes 
A total of 1,087 participants have a professional diagnosis of PD and 5,581 participants 
are healthy. Within the PD participants, we find a higher proportion of males than 
females, with males accounting for 65.8% of cases. Interestingly, this sex imbalance is 
present in the healthy participants also, with males accounting for 80.8% of the healthy 
cases. However, of the 5,314 male participants only 13.5% are PD cases. Of the 1,461 
female participants, 25.3% are PD cases. 
Although an imbalance exists between sexes (more males than females in cohorts of PD 
and health controls), the participants are well age matched with respect to the ages at 
which males report disease onset (56.6 ± 9.6 years) showing no significant difference to 
that of females (56.2 ± 9.0 years) [p = 0.53]. This finding is overall consistent with the age 
at which professional diagnosis occurs; males (58.4 ± 9.0 years) and females (57.9 ± 8.4 
years) [p = 0.44]. 
In the tapping activity, we find no difference in starting performance between males 
(135.4 ± 61.3 taps) and females (133.9 ± 58.0 taps) [p = 0.73]. Similarly, in the memory 
activity, the starting performance of males (254.5 ± 57.1) shows no significant difference 
to that of females (256.9 ± 63.2) [p = 0.74].  
In the tapping activity, the results of the Binomial proportion tests showed no statistical 
difference between the proportion of male (N = 179) to female (N = 133) participants in 
the improving [p = 0.61], deteriorating [p = 0.91], and stable [p = 0.42] phenotypes. 
Similarly, in the memory activity, the proportion of male (N = 58) and female (N = 39) 
participants in the improving [p = 0.75], deteriorating [p = 0.88], and stable [p = 0.38] 
phenotypes showed no significant differences. 
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3.4 Relationship between Motor and non-Motor Tasks 
Of the 107 participants who were in both the tapping and memory longitudinal analyses 
there were 13 HCs and 94 PDs. Figure 4 shows how these participants performed 
longitudinally in both the tapping and memory activities. 
 
Figure 4: Confusion plot of inter-activity longitudinal behaviour. Numbers quoted are the percentage of the 
population that fall into each segment. The central black figures are the percentages of all 107 participants 
in the analysis. The lower left numbers in blue are the percentage of the 13 HC participants. The lower 
right numbers in red are the percentage of the 94 PD participants. 
The HC and PD participants were well age matched with ages of 64.9 ± 7.3 and 65.5 ± 6.3 
respectively.  As the memory activity was introduced six months after the tapping activity, 
these results do not show the concurrent relationship between the activities, but rather 
how participants perform when learning two new tasks which assess different areas of 
the disease.  
4. Discussion 
In a hospital environment the collection of high frequency longitudinal data from a large 
subject group would be costly and strategically difficult. Subsequently, research objectives 
are now being turned to exploiting remotely acquired datasets, such as in the mPower 
study, to validate clinical findings in large cohorts whilst gaining new insights into the 
longitudinal characteristics of PD. In this study, we demonstrate that clinically validated 
features can be used to remotely identify task learning using smartphones. From a large 
cohort of PD subjects and healthy controls, we find that a small fraction of subjects show 
transient longitudinal behaviour which has previously gone undetected in smaller 
datasets. Furthermore, subjects with PD are more likely to show transient longitudinal 
behaviour whilst also tending to take longer to reach a steady performance in the 
alternating finger tapping test and the steady state performances are found to correlate 
better with disease severity than baseline performance. When investigating the floor-
ceiling effect in the mPower UPDRS survey, significant correlations between performance 
and severity are found within the most severe participants, but not in the less severe 
subjects, whilst many of the individual UPDRS questions show a large floor effect that is 
not found in the total UPDRS score.  
On the large mPower cohort, we have validated the clinical finding that PD participants 
show an impaired motor performance and the ability to improve the AFT activity over a 
period of five repetitions. Participants who are in the same medication state at baseline 
and at their fifth repetition showed a significant performance change. This result 
demonstrates that the change in performance is not a consequence of medication 
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response, as has previously been suggested, but rather due to practise and learning of the 
test (Anderson et al. 2014). Intuitively, we find across all subject groups and ages that 
subjects with a lower baseline performance are more likely to improve than those with a 
higher baseline performance. 
In the tapping activity, we found that only a small fraction of all subjects showed transient 
behaviour and that the PD group tended to improve by a lesser degree over the first 20 
instances than both the HC groups. This finding is unlikely to have been detected in 
previous studies due to the low subject numbers, lack of longitudinal data, and the small 
proportion of subjects showing this behaviour. The majority of subjects in all groups 
showed stable longitudinal behaviour, although the PD group was found to have a 
significantly larger proportion of subjects showing transient behaviour compared to both 
the healthy control groups. Consequently, the PD participants took a significantly larger 
number of test instances before they reached their steady state performance. These 
longitudinal variations should be incorporated into the medication response models which 
have formed the majority of the work on the mPower dataset so far (Chaibub Neto et al. 
2016; Neto et al. 2017). 
Although no impairment is seen in the PD participants at baseline in the memory activity, 
the PD participants are the only group to show a significant change between baseline and 
the fifth repetition of the activity, consistent with the tapping activity. We also find that 
subjects with a lower starting performance tend to improve by a larger degree than 
subjects with a higher starting performance. The longitudinal memory behaviour analysis 
was more restricted in participant numbers than the tapping activity meaning 
proportional tests were inappropriate and were not performed. Unlike the majority of the 
non-motor learning in PD literature, the mPower study does not utilise the Serial 
Reaction Time Test, which assesses both long and short term memory through multiple 
tests showing a repeated sequence of stimuli. Subsequently, the mPower memory activity 
does not provide a means of assessing declarative learning, which has shown significant 
impairment in PD subjects (Muslimović et al. 2007). 
In the tapping activity, we find the steady state performance is a better predictor of 
severity than baseline performance. This suggests that starting performance at a new 
motor task is less representative of disease severity than the performance after the test 
has been learnt. However, this phenomenon is not seen in the memory activity. The 
number of subjects showing learning behaviour in the memory activity is smaller than in 
the tapping activity, thus the smaller amount of longitudinal change occurring in the 
performance combined with the generally weaker baseline correlations is reflected by the 
intuitive decrease in correlation strength with SSP.  
When correlating years since diagnosis and total UPDRS for all PD participants, as shown 
in Figure 2, we find a significant correlation of moderate strength (R = 0.32, p < 0.0001); 
intuitively demonstrating that disease severity worsens with time. This finding is also 
seen when limiting our sample to the participants in each activity in the PSS. However, 
although the Section II score (motor) of UPDRS shows a similarly strong correlation with 
years since diagnosis, we find weak correlations between the Section I score (non-motor) 
and years since diagnosis. This result may be interpreted in two ways. Firstly, this could 
imply that motor deterioration is more pronounced than non-motor deterioration, which 
has also been suggested in a cohort of 707 subjects over a two year period (Antonini et al. 
2012). Secondly, accounting for the fact the UPDRS is self-assessed, it may be that 
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participants are more aware of motor deterioration than non-motor. Using longitudinal 
smartphone data and clinically assessed UPDRS collected from a larger cohort, future 
studies could make more informed inferences regarding the difference in rates of motor 
and non-motor degradation over time. Conversely, weak correlations were found between 
years since diagnosis and the baseline and steady state performance measures in both 
activities. 
In our investigation of floor-ceiling effects, we find that in both activities the performance 
of severe subjects consistently have a stronger correlation with severity scores than the 
non-severe subjects. Additionally, although very large floor effects are seen within each 
of the individual questions, neither floor nor ceiling effects are found in the total UPDRS 
score. These findings are a consequence of many subjects reporting low/mild severity for 
several questions and no severity for the majority of questions, thus, for many subjects, 
the total UPDRS severity is being diluted by the many questions being reported as zero. 
Accordingly, only subjects experiencing mild/severe symptoms in multiple aspects of the 
disease are grouped as Severe as they report many instances of mild/severe severities in 
the UPDRS survey. Hence, in the Non-Severe group, many subjects may report a severe 
impairment localised to one aspect of the disease, but no impairment in the remaining 
aspects, and therefore go undetected. This is reflected in the large divide in correlation 
strengths between feature performance and disease severities between the severe and 
non-severe groups. 
There is an imbalance between sexes in the mPower dataset with roughly 80% of all 
participants being male. We find that the imbalance between sexes in the mPower PD 
population is consistent with previous studies, demonstrating a higher incidence rate in 
males than in females. Although an imbalance exists between sexes, it is still appropriate 
to compare the performance and diagnosis metrics of the sexes as both samples contain a 
large number of participants even after their age matching. Fortunately, our Longitudinal 
Behaviour Subset is less severely affected by the sex imbalance. Binomial proportion tests 
demonstrate that the proportion of male and female participants in each L-PT is 
statistically similar, thus ruling out gender as a confounding factor in L-PT classification. 
The ‘big’ data collected through the use of smartphones is enabling multiple aspects of 
Parkinson’s disease to be studied concurrently. Determining the complex relationship 
between motor and non-motor symptoms has thus far been restricted by clinical studies 
investigating a single activity such as gait, tapping, memory, or cognition. The multiple 
activity types being completed on smartphone collection systems on a regular basis 
present the opportunity to overcome this restriction. When comparing the longitudinal 
behaviour of a small number of participants across the tapping and memory activities, we 
observe a non-diagonal relationship between their learning-phenotypes.    
A recurring limitation with remotely collected big datasets is the lack of longitudinal 
subject compliance (Arroyo-gallego et al. 2017; Bot et al. 2016). In the tapping activity, we 
found 548 (6.8%) of the initial 8,003 subjects contributed at least 20 instances. 
Furthermore, compliance levels greatly differ between HC and PD participants. Of the 
5,357 HC participants at baseline, only 236 (4.4%) contributed at least 20 instances. 
Conversely, 312 of the 1,060 PD participants (29.4%) at baseline contributed at least 20 
instances. In the memory activity, we were forced to lower the minimum number of 
instances required to be eligible for analysis to 10, resulting in 121 (12.5%) of the initial 
968 subjects being eligible. The reduced number of subjects participating in the memory 
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activity is a knock-on effect of this limitation as it was introduced over a month after the 
initial application release. Many of the participants who were active at the start of the 
study had stopped using the mPower application by the time the memory activity was 
released whilst the number of new participants enrolling in the study had plateaued. 
However, although the compliance level is relatively low, the longitudinal data from these 
datasets is still significantly larger than in previous studies. The use of passive 
monitoring (continuous data collection when the smartphone application is not actively 
being used) ensures a high level of compliance and is currently being implemented by 
several studies (Sharma et al. 2014; Zhan et al. 2016). However, this type of data is nearly 
entirely unlabelled making activity recognition and feature extraction more challenging. 
We finalize our discussion by considering future applications of our longitudinal analysis 
framework whilst speculating on techniques that may improve remote data collection. In 
this study, we focused on a single feature from each activity, however, exploring the 
longitudinal behaviour of additional features may facilitate better prediction of other 
aspects of the subset of UPDRS survey. For example, in the tapping activity, monitoring 
features pertaining to fatigue or finger displacement could act as proxy measures for 
resting tremor, for which there is a specific question in the mPower UPDRS survey. An 
additional progression of this study would be to utilize the additional gait and voice 
activities within the mPower dataset. The associated challenges in these data are the 
influence of differing environmental conditions, such as inclined walking surfaces and 
background noise, making it challenging to extract features that are robust at both the 
inter- and intra-participant level. Furthermore, these robust features would only be 
beneficial to longitudinal analyses if they are interpretable and relatable to at least one 
of the limited number of clinical severity measures. Finally, it is common in clinical based 
studies to also recruit the PD participant’s spouse; usually yielding an approximately age 
and sex balanced control participant. If volunteers of remote studies were to be 
encouraged to ask their spouse to also enrol, the resulting datasets may not only be larger, 
but may also not contain the imbalances this research has highlighted are present in the 
current dataset. 
5. Conclusion 
Using the remotely collected mPower dataset, we investigated the short-term and 
longitudinal behaviour of people with PD and HCs in a motor test and a separate non-
motor test. We found significant impairments in the motor activity on both a short and 
long term basis, whereas no such impairment existed in the non-motor test. In both tests, 
we identified a previously unseen small fraction of participants who show transient 
longitudinal behaviour, with this transient behaviour being more common in PD 
participants than in HCs. The findings in this work motivate the study of longitudinal 
performance in the additional, and more environmentally dependant, tests also being 
measured remotely on smartphones such gait and voice. 
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